Breast cancer is one of the most common malignancies in women, and is the leading cause of death worldwide for women between the ages of 40 and 55 years in the world.
San-Zhong-Kui-Jian-Tang, a Traditional Chinese Medicine Prescription, Inhibits the Proliferation of Human Breast Cancer Cell by Blocking Cell Cycle Progression and Inducing Apoptosis
Cell Proliferation Assay (XTT) Inhibition of cell proliferation by SZKJT was measured by XTT (sodium 3Ј-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene-sulfonic acid hydrate) assay. Briefly, cells were plated in 96-well culture plates (1ϫ10 4 cells/well). After 24 h incubation, the cells were treated with SZKJT (0, 100, 200, 300 mg/ml) for 48 h. Fifty microliters of XTT test solution, which was prepared by mixing 5 ml of XTT-labeling reagent with 100 ml of electron coupling reagent, was then added to each well. After 4 h incubation, absorbance was measured on an ELISA reader (Multiskan EX, Labsystems) at a test wavelength of 492 nm and a reference wavelength of 690 nm. Data were calculated as the percentage of inhibition by the following formula: inhibition %ϭ[100Ϫ(ODt/ODs)ϫ100]%. ODt and ODs indicated the optical density of the test substances and the solvent control, respectively. The concentration of 50% cellular cytotoxicity of cancer cells (IC 50 ) of test substances was calculated based on 48 h absorbance values.
Cell Cycle Analysis To determine cell cycle distribution analysis, 5ϫ10 5 cells were plated in 60 mm dishes and treated with SZKJT (100, 200 mg/ml) for 12 h. After treatment, the cells were collected by trypsinization, fixed in 70% ethanol, washed in phosphate-buffered saline (PBS), resuspended in 1 ml of PBS containing 1 mg/ml RNase and 50 mg/ml propidium iodide, incubated in the dark for 30 min at room temperature, and analyzed by EPICS flow cytometer. The data were analyzed using Multicycle software (Phoenix Flow Systems, San Diego, CA, U.S.A.).
Measurement of Apoptosis Quantitative assessment of apoptosis was analyzed by an Annexin V assay kit (BD Biosciences PharMingen, San Jose, CA, U.S.A.). Briefly, cells grown in 10 cm Petri dishes were harvested with trypsin and washed in PBS. Cells were then resuspended in binding buffer (10 mmol/l HEPES/NaOH (pH 7.4), 140 mmol/l NaCl, 2.5 mmol/l CaCl 2 ) and stained with Annexin V-FITC and PI at room temperature for 15 min in the dark. Cells were then analyzed in an EPICS flow cytometer (Coulter Electronics) within 1 h after staining. Data from 10000 cells were collected for each data file. Apoptotic cells were defined as Annexin V-positive, PI-negative cells.
Quantitative assessment of apoptotic cells was also assessed by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick endlabeling (TUNEL) method, which examines DNA-strand breaks during apoptosis by using BD ApoAlert™ DNA Fragmentation Assay Kit. Briefly, cells were incubated with 100 and 200 mg/ml SZKJT for the indicated times. The cells were trypsinized, fixed with 4% paraformaldehyde, and permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate. After being washed, the cells were incubated with the reaction mixture for 60 min at 37°C. The stained cells were then analyzed with an EPICS flow cytometer.
Assaying the Levels of p53, p21/WAF1, Fas/APO-1 and Fas Ligand (mFasL and sFasL) p53 pan ELISA, WAF1 ELISA, Fas/APO-1 ELISA and Fas Ligand ELISA kits were used to detect p53, p21/WAF1, Fas/APO-1 receptor and FasL. Briefly, cells were treated with 0, 100, and 200 mg/ml SZKJT for the indicated times. The samples of cell lysate were placed in 96 well (1ϫ10 6 per well) microtiter plates coated with monoclonal detective antibodies, and were incubated for 1 h (Fas/APO-1), 2 h (p53 or p21/WAF1) or 3 h (Fas ligand) at room temperature. It was necessary to determine the soluble Fas ligand in cell culture supernatant by using Fas Ligand ELISA kit. After removing unbound material by washing with washing buffer (50 mM Tris, 200 mM NaCl, and 0.2% Tween 20), horseradish peroxidase conjugated streptavidin was added to bind to the antibodies. Horseradish peroxidase catalyzed the conversion of a chromogenic substrate (tetramethylbenzidine) to a colored solution, with color intensity proportional to the amount of protein present in the sample. The absorbance of each well was measured at 450 nm, and concentrations of p53, p21/WAF1, Fas/APO-1 and Fas L were determined by interpolating from standard curves obtained with known concentrations of standard proteins.
Assay for Caspase-8 and -9 Activities The assay is based on the ability of the active enzyme to cleave the chromophore from the enzyme substrate: Ac-IETD-pNA (Ac-IleGlu-Thr-Asp-pNA) for caspase-8, and LEHD-pNA (Ac-LeuGlu-His-Asp-pNA) for caspase-9. Cell lysates were incubated with peptide substrate in assay buffer (100 mM NaCl, 50 mM HEPES, 10 mM dithiothreitol, 1 mM EDTA, 10% glycerol, 0.1% CHAPS, pH 7.4) for 2 h at 37°C. The release of p-nitroaniline was monitored at 405 nm. Results are represented as the percentage of change of activity compared to the untreated control.
Immunoblot Assay Cells were treated with 200 mg/ml SZKJT for specified intervals of time. Mitochondrial and cytoplasmic fractions were separated using Cytochrome c Releasing Apoptosis Assay Kit (BioVision, California, U.S.A.). For immunoblotting, the cells were lysed on ice for 40 min in a solution containing 50 mM Tris, 1% Triton X-100, 0.1% SDS, 150 mM NaCl, 2 mM Na 3 VO 4 , 2 mM EGTA, 12 mM bglycerolphosphate, 10 mM NaF, 16 mg/ml benzamidine hydrochloride, 10 mg/ml phenanthroline, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mg/ml pepstatin, and 1 mM phenylmethylsulfonyl fluoride. The cell lysate was centrifuged at 14000ϫg for 15 min, and the supernatant fraction was collected for immunoblotting. Equivalent amounts of protein were resolved by SDS-PAGE (10-12%) and transferred to PVDF membranes. After blocking for 1 h in 5% nonfat dry milk in Tris-buffered saline, the membrane was incubated with the desired primary antibody for 1-16 h. The membrane was then treated with appropriate peroxidase-conjugated secondary antibody, and the immunoreactive proteins were detected using an enhanced chemiluminescence kit (Amersham, U.S.A.) according to the manufacturer's instructions.
In Vivo Tumor Xenograft Study Female nude mice [6 weeks old; BALB/cA-nu (nu/nu)] were purchased from National Science Council Animal Center (Taipei, Taiwan) and maintained in pathogen-free conditions. MDA-MB-231 cells were injected subcutaneously into the flanks of nude mice (5ϫ10 6 cells in 200 ml). Tumors were allowed to develop for ca. 30 d until they reached ca. 75 mm 3 , when treatment was initiated. Twenty mice were randomly divided into two groups. SZKJT was dissolved in sterilized distilled water, and a nude mouse received 1000 mg/kg of SZKJT in 0.5 ml of water through a naso-gastric tube (twice a day). The control group was treated with an equal volume of normal saline. After transplantation, tumor size was measured using calipers and tumor volume was estimated according to the formula: tumor volume (mm 3 )ϭLϫW 2 /2, where L is the length and W is the width.
Statistical Analysis Data were expressed as meansϮ S.D. Statistical comparisons of the results were made using analysis of variance (ANOVA). Significant differences (p<0.05) between the means of control and SZKJT-treated cells were analyzed by Dunnett's test.
RESULTS
Effect of SZKJT on Cell Proliferation in MCF-7 and MDA-MB-231 Cell Lines As shown in Fig. 1A , SZKJT inhibited cell growth in two human breast cancer cell lines in a concentration-dependent manner, with MCF-7 being more sensitive to SZKJT-induced cell growth inhibition than MDA-MB-231. The IC 50 values of SZKJT were 103.2 mg/ml for MCF-7 and 116.2 mg/ml MDA-MB-231. Interestingly, the proliferation inhibitory effect of SZKJT on H184B5F5/ M10 normal mammary epithelial cells, IMR-90 normal lung fibroblast cells, and BNL CL.2 normal murine liver cells was not significant at the same concentrations as on tumor cells (Fig. 1B) . SZKJT Induced Apoptosis in Both MCF-7 and MDA-MB-231 A quantitative evaluation of apoptosis was sought using an Annexin V-FITC dye to detect the translocation of phosphatidylserine from the inner (cytoplasmic) leaflet of the plasma membrane to the outer (cell surface). Compared with vehicle-treated cells, 200 mg/ml SZKJT induced 48.6% and 40.6% of apoptotic cells in MCF-7 and MDA-MB-231 at 48 h, respectively (Figs. 3A, B) . Additionally, a quantitative evaluation was sought using TUNEL to detect the amount of DNA fragmentation. Compared with vehicle-treated cells, 200 mg/ml SZKJT induced 50.6% and 42.6% of cytoplasmic oligonucleosome in MCF-7 and MDA-MB-231 at 48 h, respectively (Figs. 3C, D) . The proapoptotic effect of SZKJT was also observed in a dose-dependent manner after 48 h treatment (Fig. 3E) .
Effect of SZKJT on Cell Cycle-Related Molecules We next examined the effect of SZKJT on cell cycle-regulatory molecules, including p53, p21/WAF1, cyclinD1, cyclinD2, and cyclinB. Previous reports have indicated that MCF-7 cells have a normal tumor suppression gene, p53, whereas in MDA-MB-231 cells the major protein of the p53 gene has mutated and is accompanied by the absence of p53 function. 8, 9) As shown in Fig. 4A , SZKJT failed to affect the ex- pression of p53 at any of the examined time points in MCF-7 cells, but increased the expression of p21/WAF1 in both MCF-7 and MDA-MB-231 cells (Figs. 4B, C) . Furthermore, SZKJT treatment of the cells resulted in a time-dependent decrease in the protein expression of cyclinD1, cyclinD2 in both MCF-7 and MDA-MB-231 cells (Fig. 4D) .
Fas/Fas Ligand Is Not Involved in SZKJT-Mediated Apoptosis
To establish the sequence of events occurring during SZKJT-induced apoptosis, we measured some of the molecular activity of the death receptor apoptotic pathway, including Fas/APO-1 receptor and its two ligands, mFas ligand and sFas ligand. However, treatment of either of these two cell lines with 100 or 200 mg/ml SZKJT failed to affect the levels of these proteins at any of the examined time points, including Fas/APO-1, mFas ligand and sFas ligand (data not shown). In addition, SZKJT also failed to affect the activation of caspase-8 in both MCF-7 and MDA-MB-231 cells (data not shown).
SZKJT Induces the Execution of Apoptosis through Activation of the Mitochondrial Pathway
To investigate the mitochondrial apoptotic events involved in SZKJT-induced apoptosis, we first analyzed the changes in the levels of pro-apoptotic protein Bax and Bak, and anti-apoptotic protein Bcl-2. Western blot analysis showed that treatment of MCF-7 and MDA-MB-231 cells with SZKJT increased Bax and Bak protein levels (Fig. 5A) . In contrast, SZKJT decreased Bcl-2, which led to an increase in the proapoptotic/ antiapoptotic Bcl-2 ratio (Fig. 5A) .
Cytosolic extracts were prepared under conditions to preserve the mitochondria, and cytosolic cytochrome c protein levels were measured by immunoblotting analysis. Figure 5B shows that the cytosolic fraction from untreated MCF-7 and MDA-MB-231 cells contained no detectable amounts of cytochrome c, whereas it did become detectable after 12 h of 200 mg/ml SZKJT treatment in both MCF-7 and MDA-MB-231 cells.
Hallmarks of the apoptotic process include the activation of cysteine proteases, which represent both initiators and executors of cell death. Upstream caspase-9 activities increased significantly as shown by the observation that treatment with SZKJT increased caspase-9 activity in both MCF-7 and MDA-MB-231 cells. This is consistent with the release of cytochrome c into the cytosol (Figs. 5C, D) .
To verify the relation of apoptosis and cytotoxicity in SZKJT-treated breast cancer cells, we used pan-caspase inhibitor to block caspase activity in both cell lines and determine whether the cell proliferation inhibition was changed after SZKJT treatment. Blocked of caspases activation resulted in a completely decreased in SZKJT-mediated proliferation inhibition in both cell lines (Fig. 5E ), suggesting that SZKJT inhibits cell proliferation inhibition by apoptosis induction.
SZKJT Inhibits Tumor Growth in Nude Mice To determine whether SZKJT inhibits tumor growth in vivo, equal numbers of MDA-MB-231 cells were injected subcutaneously into both flanks of the nude mice. Tumor growth inhibition was most evident in mice treated with SZKJT at 1000 mg/kg, (twice day) where ca. 40% reductions in tumor size were observed, in contrast with mice treated with the vehicle (Figs. 6A, B) . No sign of toxicity, as judged by parallel monitoring body weight, was observed in SZKJT-treated mice.
DISCUSSION
Breast cancer is the most common neoplasm in human in both developed and developing countries. 10, 11) In our study, we have found that SZKJT effectively inhibits tumor cell growth in vitro, concomitant with induction of cell cycle arrest and apoptosis, and inhibits tumor cell growth in nude mice. Furthermore, because SZKJT do not exhibit any significant toxicity on various normal cells, this suggests that SZKJT possesses selectivity between normal and cancer cells. This selection of SZKJT to cancer cells may be related to the different genomic stability between cancer and normal cells. 12) Eukaryotic cell cycle progression involves sequential activation of Cdks, whose activation is dependent upon their association with cyclins. 13) A complex formed by the associa- tion of Cdc4/6 and cyclin D1/D2 plays a major role at entry into S phase. 14, 15) Cell cycle progression is also regulated by the relative balance between the cellular concentration of cyclin-dependent kinase inhibitors (CKIs), such as members of the cyclin-dependent kinase-interacting protein/cyclin-dependent kinase inhibitory protein (CIP/KIP) and inhibitor of cyclin-dependent kinase (INK) families, and that of cyclin-CDK complexes. The Cip/Kip family, including p21/WAF1, and p27/KIP, bind to cyclin-CDK complexes and prevent kinase activation and subsequently blocks the progression of cell cycle at G0/G1 or G2/M phase. 15, 16) In our result, we found that SZKJT treatment not only causes a significant increase in the expression of p21 both in MCF-7 and MDA-MB-231 cells, but also decreases the expressions of cyclinD1, and cyclinD2. Thus, it is reasonable to postulate that SZKJT treatment may cause cell cycle arrest by regulating the expressions of G0/G1 regulating proteins.
Two major distinct apoptotic pathways have been described for mammalian cells. One involves caspase-8, which is recruited by the adapter molecule Fas/APO-1 associated death domain protein to death receptor upon Fas ligand binding. 3, 17) We did not observe any alteration of either Fas/APO-1 or Fas ligand (mFas ligand and sFas ligand) expression or caspase-8 activation in SZKJT-treated MCF-7 and MDA-MB-231 cells. On the other hand, SZKJT treatment resulted in a significant increase of Bax and Bak expression, and decreased the amount of Bcl-2, suggesting that changes in the ratio of proapoptotic and antiapoptotic Bcl-2 family proteins might contribute to the apoptosis-promotion activity of SZKJT. These regulatory effects of SZKJT on the Bcl-2 family are correlated with the release of cytochrome c from the mitochondria into the cytoplasm and the activation of caspase-9.
In this study, we concluded that the molecular mechanisms during SZKJT-mediated growth inhibition in MCF-7 and MDA-MB-231 cells involved the (1) induction of apoptosis, (2) blockade of cell cycle progression by regulating cell cycle-related factor, (3) trigger of mitochondrial pathway, (4) modulation of Bcl-2 family protein, and (5) inhibition of cancer growth in nude mice. We demonstrated that SZKJT may be a promising chemotherapy agent for treating breast cancer.
